

the Drawing and the claims respectively of the above-identified application pursuant to 37 C.F.R. 121. Such amendment is being made by submission of replacement paragraphs for the Specification, by a substitute sheet of drawing, and by a sheet presenting the amended claim language in clean copy form, for the changes listed below:

In the Specification:

Replacement amended paragraphs in clean copy format are enclosed for the text beginning at:

Page 24, line 13;

Page 26, lines 14, 22, 27, and 32;

Page 28, Table 4; and

Page 46, line 9.

In the Drawing:

A substitute sheet for Figs 1A and 1B is enclosed wherein the amendments are shown in red ink.

In the Claims:

Pending dependent claims 12, 13 and 14 respectively are amended and the amended language of each claim is presented in clean copy format.

1 including wound healing and myocardial infarction [Gallo et al., Proc. Natl. Acad. Sci.  
2 USA 91: 11035-11039 (1994); Li et al., Circ. Res. 81: 785-796 (1997)]; and the native  
3 peptide has been shown to be taken up rapidly by a number of different cell types  
4 including meschymal cells and endothelial cells [Chan, Y.R. and R.L. Gallo, J. Biol.  
5 Chem. 273: 28978-28985 (1998)].

6  
7 The PR-39 peptide grouping

8 Native PR-39 peptide is composed of the 39 amino acid sequence shown below  
9 (and also by Table 4).

10  
11 PR-39: Arg-Arg-Arg-Pro-Arg-Pro-Pro-Tyr-Leu-Pro-Arg-Pro-Arg-Pro-Pro-Phe-  
12 Phe-Pro-Pro-Arg-Leu-Pro-Pro-Arg-Ile-Pro-Pro-Gly-Phe-Pro-Pro-Arg-Phe-  
13 Pro-Pro-Arg-Phe-Pro [SEQ ID NO:1]

14  
15 As conventionally known and reported [see for example, U.S. Patent No.  
16 5,654,273], the specific peptide can be substituted using conservative substitutions of  
17 amino acids having the same or functionally equivalent charge and structure, except for  
18 the required amino acid sequence "Arg-Arg-Arg" at the N-terminus and the intermediate  
19 amino acid sequences "Pro-Pro-X-X-Pro-Pro-X-X-Pro" and "Pro-Pro-X-X-X-Pro-Pro-X-  
20 X-Pro" where X can be substituted freely using any amino acid. Thus, all of the  
21 preferred substituted amino acid sequences are of about the same size and each differ  
22 from the native PR-39 peptide sequence only by substitutions in the intermediate portions  
23 of the structure.

1 Merely as illustrative examples and preferred embodiments of the broad  
2 membership constituting this PR-39 derived oligopeptide family, the members comprising  
3 15, 11 and 8 amino acid residues respectively in length are presented below as the PR15,  
4 PR11, and PR8 entities respectively. For comparison purposes only, the complete amino  
5 acid sequence of the native PR-39 peptide is presented as well.

6  
7  
8 PR-39: 1 2 3 4 5 6 7 8 9 10 11 12 13  
9 Arg-Arg-Arg-Pro-Arg-Pro-Pro-Tyr-Leu-Pro-Arg-Pro-Arg-  
10 14 15 16 17 18 19 20 21 22 23 24 25 26  
11 Pro-Pro-Pro-Phe-Phe-Pro-Pro-Arg-Leu-Pro-Pro-Arg-Ile-  
12 27 28 29 30 31 32 33 34 35 36 37 38 39  
13 Pro-Pro-Gly-Phe-Pro-Pro-Arg-Phe-Pro-Pro-Arg-Phe-Pro  
14 [SEQ ID NO:2]  
15  
16  
17

18 PR-15: 1 2 3 4 5 6 7 8 9 10 11 12 13  
19 Arg-Arg-Arg-Pro-Arg-Pro-Pro-Tyr-Leu-Pro-Arg-Pro-Arg-  
20 14 15  
21 Pro-Pro [SEQ ID NO:3]  
22  
23  
24  
25

26 PR-11: 1 2 3 4 5 6 7 8 9 10 11  
27 Arg-Arg-Arg-Pro-Arg-Pro-Pro-Tyr-Leu-Pro-Arg [SEQ ID NO:4]  
28  
29  
30

31 PR-8: 1 2 3 4 5 6 7 8  
32 Arg-Arg-Arg-Pro-Arg-Pro-Pro-Tyr [SEQ ID NO:5]  
33  
34  
35

#### The PR-39 Oligopeptide Collective

36 Terminology and nomenclature often pose problems for the reader as to what  
37 precisely is meant. Accordingly, for definitional purposes, avoidance of ambiguities, and  
38 clarity of understanding, the following terms and titles will be employed herein. The term  
39 "PR-39 peptides grouping" includes by definition the native PR-39 structure and all

Table 4:

(1) GENERAL INFORMATION:  
 (i) APPLICANT: Children's Medical Center Corporaton  
 (ii) TITLE OF INVENTION: Synducin Mediated Modulation of Tissue Repair  
 (iii) NUMBER OF SEQUENCES: 4  
 (iv) CORRESPONDENCE ADDRESS:  
 (A) ADDRESSEE: Patrea L. Pabst  
 (B) STREET: 2800 One Atlantic Center  
 1201 West Peachtree  
 (C) CITY: Atlanta  
 (D) STATE: Georgia  
 (E) COUNTRY: USA  
 (F) ZIP: 30309-3450  
 (v) COMPUTER READABLE FORM:  
 (A) MEDIUM TYPE: Floppy disk  
 (B) COMPUTER: IBM PC compatible  
 (C) OPERATING SYSTEM: PC-DOS/MS-DOS  
 (D) SOFTWARE: PatentIn Release #1.0, Version #1.25  
 (ix) TELECOMMUNICATION INFORMATION:  
 (A) TELEPHONE: (404)-873-8794  
 (B) TELEFAX: (404)-815-8795  
 (2) INFORMATION FOR SEQ ID NO:1:  
 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 39 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear  
 (ii) MOLECULE TYPE: peptide  
 (iii) HYPOTHETICAL: NO  
 (iv) ANTI-SENSE: NO  
 (x) PUBLICATION INFORMATION:  
 (A) AUTHORS: Lee, Jong-Youn  
 Boman, Hans G.  
 Mutt, Viktor  
 Jornvall, Hans  
 (B) TITLE: Novel Polypeptides And Their Use  
 (C) JOURNAL: PCT WO 92/22578  
 (G) DATE: 12/23/92  
 (K) RELEVANT RESIDUES IN SEQ ID NO:1: FROM 1 TO 39  
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:  
 Arg Arg Arg Pro Arg Pro Pro Tyr Leu Pro Arg Pro Arg Pro  
 Pro Pro 1 5 10  
 15  
 Phe Phe Pro Pro Arg Leu Pro Pro Arg Ile Pro Pro Gly Phe  
 Pro Pro 20 25 30  
 Arg Phe Pro Pro Arg Phe Pro [SEQ ID NO:6]  
 35

Experiment 6:

To demonstrate the efficiency of shorter-length peptides which collectively are members of the PR-39 derived oligopeptide family in stimulating angiogenesis in-vivo, a novel peptide, PR11, composed of the first 11 amino acid residues [N-terminal end] of the native PR-39 sequence was purposely synthesized. The amino acid sequence of PR11 is as follows:

1	2	3	4	5	6	7	8	9	10	11
Arg	Arg	Arg	Pro	Arg	Pro	Pro	Tyr	Leu	Pro	Arg

[SEQ ID NO:7]

To introduce the short-length PR11 peptide in-vivo, a mouse Matrigel assay system was utilized. In sum, either 5  $\mu$ g/ml of PR11 peptide or 5  $\mu$ g/ml of native PR-39 peptide were individually placed into a growth factor-depleted Matrigel pellet; and then each prepared Matrigel pellet was inserted into the peritoneal cavity of a mouse. After 14 days intraperitoneal placement, each pellet was removed from its living host; and each pellet was examined for evidence of new vascularity. The results are graphically presented by Fig. 7. Note that the bar graph of Fig. 7 shows the number of blood vessels [mean  $\pm$  SD] per 10 high power fields (HPF).

As evidenced by Fig. 7, the analysis of Matrigel pellet vascularity after 14 days incubation in-vivo demonstrated significant induction of angiogenesis in both the PR11 and the native PR-39 pellets. The control Matrigel pellets, however, showed no evidence of angiogenesis as such. Clearly therefore, the short-length PR11 peptide is fully efficacious and effective in stimulating angiogenesis in-vivo.